Antitumour efficacy of TRAIL: an immunotherapeutic approach for the treatment of skeletal malignancies

TRAIL 的抗肿瘤功效：一种治疗骨骼恶性肿瘤的免疫治疗方法

• 批准号: nhmrc : 565357
• 负责人: Prof Andreas Evdokiou
• 金额: $ 30.61万
• 依托单位: The University of Adelaide
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2009
• 资助国家: 澳大利亚
• 起止时间: 2009-01-01 至 2012-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/antitumour-efficacy-trail-skeletal-malignancies/77645
• 关键词: Antitumour; efficacy; TRAIL; immunotherapeutic; approach

The most serious clinical problem with patients with solid tumours is metastasis to bone, which leads to complications that can cause erosion of the patient's quality of life, and eventually death. TRAIL is a new cancer therapeutic that selectively kills cancer cells while sparing normal cells. The use of TRAIL agonistic antibodies that do not bind OPG and have increased serum half life offers an exciting approach for the treatment of skeletal malignancies that is non toxic and safe.

实体瘤患者最严重的临床问题是骨转移，这导致并发症，可能导致患者生活质量下降，最终死亡。TRAIL是一种新的癌症治疗药物，它选择性地杀死癌细胞，同时保留正常细胞。使用不结合OPG并具有增加的血清半衰期的TRAIL激动性抗体提供了一种无毒且安全的治疗骨骼恶性肿瘤的令人兴奋的方法。